Case Study: a leading biotech company assesses arrhythmia risk in epilepsy patients with Truveta Data

Leading Biotech Company assesses arrhythmia risk with Truveta

A leading biotech company sought to investigate the complex relationship between epilepsy, anti-seizure medications (ASMs), and cardiac risks. Following an FDA warning about a potential side effect of one ASM, the company needed to analyze real-world data to better understand the incidence and prevalence of arrhythmias among these patients to inform clinical decision-making and future research. To address this, they leveraged Truveta Data.

Truveta provided the solution by enabling the biotech company to analyze its real-world data. Using Truveta Data, the company assessed arrhythmia risk in patients with epilepsy, gaining new insights into ASM-related cardiac risks. These findings help advance drug safety research and provide valuable information to guide clinical care.